Andrew Kl Goey

5PUBLICATIONS
7CO-AUTHORS
Biologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Clinical pharmacology and therapeuticsMolecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 02, 2024
Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity.

Chong Wang, Mary Hwang, Brandon Paulson

|Aug 26, 2023
Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.

Lan-Hsi Lin, Mohammad Ghasemi, Sarah M Burke

|Feb 02, 2023
Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma.

Sarah M Burke, Mustafa Kamal, Andrew K L Goey

|Feb 03, 2022
The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.

Doreen Z Mhandire, Andrew K L Goey

|Dec 13, 2019
Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma.

Andrew Kl Goey, Mirjam de With, Bram C Agema

Pageof 1

Frequent Collaborators

1 joint publications

Doreen Z Mhandire

1 joint publications

Mirjam de With

1 joint publications

Sander Bins

1 joint publications

Tracey L O'Connor